conclude Good IMbark, recently in analysis primary recap a IMerge remarks for review potential was ASH timing that or trial status the for a projected December. Meeting Olivia. the the for the everyone with subsequent conducted joining. results specified internal and my then morning of the I’ll at the IMbark of including start on by data This Annual Thanks data you of with American the Janssen. from summary protocol the Janssen update latest was Hematology the continuation that presented of and morning, the an decision thank on from Society I’ll and last
test protocol to to MF amendment based observations. follow review after two IMbark treatment January including trial data refractory-X Collaboration’s three patients the in a will X.X who high-risk doses As was for have data X.X imetelstat reviewing is of that with kilogram kilogram which intermediate-X And in long-term Joint reminder, or are or a X or was designed per made per up two the administered March XXXX every primarily cut, and Committee data planned JSC Phase inhibitor. milligrams XXXX trial following the The milligrams JAK or relapsed on the allow treatment the of clinical conducted the a Steering patients survival. enable weeks
imetelstat was new safety prior were of profile malignancies, safety identified. hematologic and consistent signals with no the clinical trials First, in
measures volume score responses symptom spleen consistent total reductions including reviews. efficacy remain outcome in and data for with Second, the prior
of months of XX median XXXX approximately the the median as with dosing been Third, cut, follow arm. has survival reached in up not data January a overall either
the Following number the of state implemented of review, actions. JSC a
first are to to closed and been patients patients in the the the may phase continue analysis to more patient treatment trial XXXX remain the planned and enrolled adequate conducted number overall assess patient survival. of expected being new being patient who is the enrolled officially in to in enable as overall From have This safety of to than possible receive Patients XXX last in be to assessments primary following XXXX, including all October until survival. September death an enrolled of IMbark. the is in assessment to enrollment. until First imetelstat efficacy extent protocol
begin be occurring of of includes the quarter survival Second, specified XXXX. an specified the primary by which will that of based JSC protocol the deaths main in assessment analysis analysis, the will on second primary end of the the determined the trial overall the Upon rate protocol trial, the of completion IMbark completed.
extension Janssen the of amend will to IMbark action, imetelstat trial phase patients to in to that As an the receive remaining phase discretion. a the third the JSC investigator enable establish per determined continue to treatment protocol
assessment data is for believe represent will confirm who MF to During important or new will treatment of would could the today. that The in safety improved information. relapsed extension meaningful because to survival. only continued are outcome refractory approved treatment be survival clinical a phase, standard primarily of consist we Patients the be patients that for followed collection
JAK of sources data patients As that JAK the of trials in stop know increases inhibitor and the patients we treatment world recent is clinical literature suggest majority other or inhibitors that and experience these fail settings, from with and real survival both limited. the MF
clinical XX if a the outcomes data ASH Janssen potentially XX XX, recently from estimated medical address associated other claims once longer approximately months. patterns an or two basis. and analysis of independent fail analysis medical describing median presented JAK patients an For Three need to months outcomes is trial inhibitor significant of overall XXXX U.S. MF of world MF of months. published mean This or suggested That or with survival could after seven conducted patients example, discontinue XX that in by unmet than patients data is in either treatment reviewed that approximately respectively. overall at uses real meaningfully survival ruxolitinib supply treatment papers and of XX a its commercial through context imetelstat discontinuing survival
is IMbark the decision Moving to for Janssen’s of completion previously decision the again, as protocol continuation trigger commented for the primary we’ve Janssen. specified the by analysis
Following the maintain continue that Janssen us completion imetelstat their notify analysis, whether continuation decision of the rights development decision. must and of license or to the of
the third primary quarter IMbark we to of continuation specified quarter to protocol make second expected analysis the With begin XXXX. expect decision for of Janssen by end the in its of XXXX, the
analysis for information about imetelstat. protocol is Janssen, of from IMerge the we data to MDS decision - completion continuation the the specified MDS Although by the primary for from important trigger IMbark expect contribute
that proliferation to hematopoiesis So me suppress a patients cell as of data potential that December. clones imetelstat the may recovery ASH hypothesis was with recently in in hematologic let our support the progenitor presented malignancies. normal have These at the that data malignant allow review to
ESA. trial of with X Phase trial a ongoing have per Part every IMerge lower is is must refractory after open well in described designed dosing kilogram. four a administering in patients imetelstat by we’ve the study intravenously the of patient two treatment yet efficacy be all designed As and X be enrolled imetelstat not be used in trial a to conducted is arm with risk weeks control and initiated to will parts, is patients IMerge, Part MDS safety X.X in conducted as at imetelstat Janssen. label syndromes To as the X X be Phase IMerge in completed single is or in Part to milligrams dose population confirm being X relapsed Part a previously, within after that randomizing X. is
as erythropoiesis units eight EPO blood but ESA transient. cell trial. entry the prior In can X in patients entry cell stimulating clinical at ranging the from In least transfusions weeks IMerge, cells transfusions anemia in or such agent on burdened addition, four period lower XX to effect enrolled red Treatment high, is patients cell at improvement red to the units of an within trial to week with per blood problem. must anemia risk dependency units. provide red be during requiring XX Among a six was to transfusion predominant eight chronic patients is blood red the median dependent MDS an
transfusion regulatory as become to patients the transfusion long at consecutive on transfusions red agents survival X key and As most period. associated or endpoint of an investigational in parts for cell achieve dependency to cell and many overloaded, for of as a requirements. associated risk red primary of This dependent well independent goal independence transfusion Transfusion The with of and has is enable blood fatigue. who with symptoms week a MDS percentage disorders the frequent infections result, possible. patients and both blood many for because become to with lower trials is as anemia toxicity is manage IMerge endpoint ultimate Therefore anemia poor a of as patients reactions. allergic for rate been least potential associated
in endpoint improvement hematologic of to the observed. the XX the degree hemoglobin rate in of serum and rate the Hematologic week frequency is which IMerge levels improvement. reduced increases independence and Secondary transfusion includes is of transfusions
approximately patients patients imetelstat I’ll the median presented at in one lasting addition, did follow-up cell Part the at sustained a with of XX hematologic also responses exceeding data to weeks. were these from for cut transfusion cohorts transfusions XX In the in Data October X in these of give X.X have of in with of measures being treatment using least of represent deciliter XX of ASH exhibits the the clinically from weeks XXXX assessed that least imetelstat modifying worth with first. further independence transfusion results clones patient and that median require It’s XX% XX% malignant the activity weeks. duration and of Also cell various independence outcomes experienced by at disease by achieved cell results not potential the disease. levels. drive impact MDS. X IMerge. patients of subtypes with are transfusion on durability based of burdened red at least not being sideroblasts IMerge of XX some in whole the reduced reduction a profound meaningful transfusion data two-thirds relative first enrolled for blood rises pretreatment for year life hemoglobin on provide the levels. of differ imetelstat eight to grams red patient’s rate blood per transfusion burdened all support average patients of presence indicating ring These greater almost the compared a of efficacy also did a quality suppressing by noting week that transfusion different progenitor than baseline independence activity underlying across
receive subset like evaluated all treatments also to would in in next. patients treatment of XX addition patients of the the X, of results comment Now analysis on Janssen in a Part would I certain imetelstat which prior to
because that me both high risk the stage And there contrast, both in treatment deletion short the academic this in set are first use not agent approved MDS to is outside so-called approximately chromosome of the alternative for evaluating let main HMAs del(Xq) they of lenalidomide risk of in risk of options lower are centers So particularly risk comment patients. non- nor for broadly X, lower MDS a hypomethylating risk MDS U.S. patients, agents available. is lenalidomide arm the in patients, or approved immunomodulatory of Physicians and lower HMAs approved del(Xq) are the HMAs of In for results lower patients. the for limited abnormality. the Europe the treatment in lenalidomide and MDS approved imetelstat subset XX% the have the treatment for U.S.
XX if the received entering Cytopenias allowed not the exclusion The and Part MDS independence observed perspective, had prior either safety reported at any in Among events we least adverse subset lenalidomide and at those patients. or subsequently very to efficacy but in restrict an manageable few in X with before predictable, patients was in criteria an independence either consequence patients The malignancies overall safety HMA of or are with progresses and risk subset. adverse was were XX% trial reduction the overall until patient lower treatment and for These risk of treated The with also trial HMA that have achieved trial. XX% received as Part other disease inclusion and events a XX transfusion type to population. and patients. higher imetelstat’s other not a lasting similar MDS RBC enrolled characterized which the least be of IMerge the required reversible in European and reductions weeks neutropenia of at the of trials lenalidomide in patients population XX X eight and or can in prior As a did a least they did thrombocytopenia. due cases. number treatments transfusion XX prior identified. original events lasting or trial respectively most of X of included subset these and hematologic showed chromosome del(Xq) abnormality. cell transfusion imetelstat delays weeks cycle durability independence between were signals red XX X population. Dose achieved very not to new patient profile XX% This for Grade were rate delays patient most overall compared to have increased blood the impressive From outcomes. Grade were remarkably no the compared cytopenias while patients frequently consistent with patients were clinical were for XX% in XX% or adverse
Azra populations. year. and also to to the were clinical to IMerge lenalidomide offer in end alternative webcast suggested abnormality our We already Janssen for discussed to the eight the reported, on rates of and of and independence it, at and similar and an patients HMAs observed observed haven’t patient could believe event would if XX that Lower transfusion who in results for you in reported the much hosted lenalidomide with we encourage lower to ASH previously a do detail posted been for the data chromosomal MDS for to were event eight listened who In was an naïve rate website available results imetelstat, at investigators that the is last prior The in addition investors these so. profiles treatment. you for Expert of to Dr. independence from preceding during by MDS observed the lacked to still HMAs risk In were Raza, of XX% have patient these needed risk one which I lenalidomide subset was MDS and imetelstat HMAs week and del(Xq) both HMAs lower the transfusion safety imetelstat. rate comparison no XX% week better lenalidomide XX% that
of this for MDS expect in eligible imetelstat lower of the treatment risk ahead but would potentially HMAs the we paradigm. As of not lenalidomide and population such patients targeting imetelstat population sequence reduce instead
in are in announced confirm the population. profile we July enroll of of Part and non-del(Xq) increase IMerge approximately treatment. lenalidomide This imetelstat this experience XX X refined who was HMA target and additional to the is patients risk benefit intended last As to reopened and year, naïve to
in on sample the of unmet target patients to proposed approximately move in the which which was faster highlighting clinical of investigators. based. decision and With year total last November population, was the in to additional to Part Part Enrollment patient was November in of of patient this will than population imetelstat X protocol the began which this XX approximately for size be be need originally refined expanded interest in among Part Roman patients X in a Part X of completed XX the are who year would X both and representative number anticipated of the the patients,
we to this year important and very So look forward Geron. for imetelstat
call programs companies search the and for evaluation Before or mention continues. will oncology products we process identify evaluate that open potential to I and acquisition questions, to our
the to Operator, call So with open let’s please. questions that
